Clinical Trial

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Study acronym: DARE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-09
Trial Details
NCT Number NCT04567420
Lead Sponsor Criterium, Inc.
Conditions Breast Cancer
Enrollment 70 participants
Start Date 2021-02-09
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08